Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Loyal Valley Capital

Founders Andy Lin

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 91
Average round size
info
The average size of a deal this fund participated in
$108M
Portfolio companies 76
Rounds per year 10.11
Lead investments 30
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.15
Exits 15
Key employees 4
Stages of investment
Late Stage Venture
Private Equity

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Life Science
Summary

The venture was found in Asia in China. The leading representative office of defined VC is situated in the Shanghai.

The fund has no exact preference in a number of founders of portfolio startups. For fund there is a match between the location of its establishment and the land of its numerous investments - China. Among the most popular fund investment industries, there are Financial Services, Mobile Apps. Among the most popular portfolio startups of the fund, we may highlight Bilibili, Shanghai Henlius, GeneCast Biotechnology. Besides, a startup needs to be aged 6-10 years to get the investment from the fund.

The top amount of exits for fund were in 2018. The common things for fund are deals in the range of 50 - 100 millions dollars. The fund is constantly included in 2-6 investment rounds annually. When the investment is from Loyal Valley Capital the average startup value is more than 1 billion dollars. The important activity for fund was in 2019. Comparing to the other companies, this Loyal Valley Capital performs on 4 percentage points more the average number of lead investments. Speaking about the real fund results, this VC is 13 percentage points more often commits exit comparing to other organizations.

The standard case for the fund is to invest in rounds with 4-5 partakers. Despite the Loyal Valley Capital, startups are often financed by Shenzhen Capital Group, TriWise Capital, Tencent Holdings. The meaningful sponsors for the fund in investment in the same round are Tencent Holdings, CITIC Capital Holdings, CICC. In the next rounds fund is usually obtained by Tencent Holdings, CITIC Capital Holdings, Bertelsmann Asia Investments.

The overall number of key employees were 4.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Loyal Valley Capital:
Typical Co-investors
Loyal Valley Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Loyal Valley Capital:

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Blackmont Capital Canada, Ontario, Toronto
Braincapital -
Bright Link Ventures England, London, United Kingdom
Chinergy Capital Anhui, China, Wuxi
CNBB Venture Partners Rotterdam, The Netherlands, Zuid-Holland
Crossover Austin, Texas, United States
Greenspace Canada, Ontario, Toronto
OTF Jasoor Ventures Masqat, Muscat, Oman
Soliton China, Huangpu, Shanghai
The New York Times New York, New York, United States

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Core Medical Technology

Manufacturing
Medical
Medical Device
$30M17 Apr 2023 Shenzhen, Guangdong, China

Surgerii Technology

Medical
Robotics
04 Apr 2023 Haidian District, Beijing, China

Bowang Pharmaceutical

Biotechnology
Product Research
$61M23 Mar 2023 Jiading, Shanghai, China

Zhishan Weixin Biotechnology

Biotechnology
Health Care
Product Research
$309K01 Feb 2023 Chengdu, Sichuan, China

Jinyuansheng

Clean Energy
Energy
$154M15 Aug 2022 Shanghai, Shanghai, China

Medilink Therapeutics

Biotechnology
Genetics
Therapeutics
$70M14 Mar 2022 Gusu District, Jiangsu, China

Peijie Hotpot

Catering
Hospitality
Restaurants
$15M17 Jan 2022 Jiangbei, Chongqing, China

Sciwind Biosciences

Biotechnology
Health Care
Pharmaceutical
$69M11 Oct 2021 Shangcheng District, Zhejiang, China

Leads Biolabs

Biotechnology
Health Care
Pharmaceutical
$100M08 Oct 2021 Nanjing, Jiangsu, China
News
Arctic Vision Closes Over US$100M Series B Financing

– Arctic Vision is a Shangai, China-based clinical-stage ophthalmology company focused on developing innovative therapies for pan-ocular diseases.
– The company closed an over US$100m Series B financing.
– The round was led by Loyal Valley Capital, with participation from Tencent, Octagon Capital, and Dr. Adrian Cheng.
– The proceeds will continue to support the progress of Arctic Vision’s pipeline, including clinical developments, registrational activities, and commercialization; as well as the establishment of in-house R&D capabilities; business development, and organizational growth.

Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development

– Medilink Therapeutics Raises $50 Million in Series A Financing To Accelerate Next-Generation Conjugated Drugs Research & Development
– The financing includes a series-A1 round led by Apricot Capital, and a series-A2 round co-led by Loyal Valley Capital and Qiming Venture Partners.
– Medilink Therapeutics was established in 2020 by a sophisticated team of industrial veterans.
– Medilink has high ambitions for its ADC R&D to be globally competitive, and meet the needs of global patients in the future.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Loyal Valley Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 91
Average round size 108M
Rounds per year 10.11
Peak activity year 2018
Lead investments 30
Follow on index 0.15
Exits 15
Group Appearance index 0.64

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Core Medical Technology

Manufacturing
Medical
Medical Device
$30M17 Apr 2023 Shenzhen, Guangdong, China

Surgerii Technology

Medical
Robotics
04 Apr 2023 Haidian District, Beijing, China

Bowang Pharmaceutical

Biotechnology
Product Research
$61M23 Mar 2023 Jiading, Shanghai, China

Zhishan Weixin Biotechnology

Biotechnology
Health Care
Product Research
$309K01 Feb 2023 Chengdu, Sichuan, China

Jinyuansheng

Clean Energy
Energy
$154M15 Aug 2022 Shanghai, Shanghai, China

Medilink Therapeutics

Biotechnology
Genetics
Therapeutics
$70M14 Mar 2022 Gusu District, Jiangsu, China

Peijie Hotpot

Catering
Hospitality
Restaurants
$15M17 Jan 2022 Jiangbei, Chongqing, China

Sciwind Biosciences

Biotechnology
Health Care
Pharmaceutical
$69M11 Oct 2021 Shangcheng District, Zhejiang, China

Leads Biolabs

Biotechnology
Health Care
Pharmaceutical
$100M08 Oct 2021 Nanjing, Jiangsu, China
Crunchbase icon

Content report

The following text will be sent to our editors: